Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular EventsEconomic Evaluation of the HOPE (Heart Outcomes Prevention Evaluation) Study for Germany from the Statutory Health Insurance Perspective

被引：0
|
作者：
Peter K. Schädlich
Josef Georg Brecht
Badrudin Rangoonwala
Eduard Huppertz
机构：
[1] InForMed GmbH — Outcomes Research and Health Economics,
[2] Bureau Itzehoe,undefined
[3] Aventis Pharma Deutschland GmbH,undefined
来源：
PharmacoEconomics | 2004年 / 22卷
关键词：
Ramipril; Target Variable; Statutory Health Insurance; Heart Outcome Prevention Evaluation; Microvascular Diabetic Complication;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: In the HOPE (Heart Outcomes Prevention Evaluation) trial, ramipril (compared with placebo) significantly reduced cardiovascular death and all-cause mortality as well as the incidence of costly cardiovascular events, such as myocardial infarction, revascularisation, stroke, cardiac arrest, hospitalisation due to heart failure and worsening angina pectoris, new-onset diabetes mellitus and microvascular diabetic complications.
引用
收藏
页码：955 / 973
页数：18
相关论文
共 50 条
  • [41] Cost effectiveness of treating high-risk individuals aged 45-65 years with statins in Germany for primary and secondary prevention of coronary heart disease from the perspective of the social security system
    Hinzpeter, B
    Klever-Deichert, G
    Lauterbach, KW
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 1999, 1 (0M) : M33 - M38
  • [42] Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study
    Blankenberg, Stefan
    McQueen, Matthew J.
    Smieja, Marek
    Pogue, Janice
    Balion, Cynthia
    Lonn, Eva
    Rupprecht, Hans J.
    Bickel, Christoph
    Tiret, Laurence
    Cambien, Francois
    Gerstein, Hertzel
    Muenzel, Thomas
    Yusuf, Salim
    CIRCULATION, 2006, 114 (03) : 201 - 208
  • [43] Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the heart outcomes prevention evaluation (HOPE) Study
    Blankenberg, Stefan
    McQueen, Matthew J.
    Smieja, Marek
    Pogue, Janice
    Balion, Cynthia
    Lonn, Eva
    Rupprecht, Hans J.
    Bickel, Christoph
    Tiret, Laurence
    Cambien, Francois
    Gerstein, Hertzel
    Muenzel, Thomas F.
    Yusuf, Salim
    CIRCULATION, 2006, 114 (18) : 871 - 871
  • [44] Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
    Bosch, Jackie
    Lonn, Eva M.
    Jung, Hyejung
    Zhu, Jun
    Liu, Lisheng
    Lopez-Jaramillo, Patricio
    Pais, Prem
    Xavier, Denis
    Diaz, Rafael
    Dagenais, Gilles
    Dans, Antonio
    Avezum, Alvaro
    Piegas, Leopoldo S.
    Parkhomenko, Alexander
    Keltai, Kati
    Keltai, Matyas
    Sliwa, Karen
    Held, Claus
    Peters, Ronald J. G.
    Lewis, Basil S.
    Jansky, Petr
    Yusoff, Khalid
    Khunti, Kamlesh
    Toff, William D.
    Reid, Christopher M.
    Varigos, John
    Joseph, Philip
    Leiter, Lawrence A.
    Yusuf, Salim
    EUROPEAN HEART JOURNAL, 2021, 42 (31) : 2995 - +
  • [45] Cost-effectiveness of cardiovascular magnetic resonance in the diagnosis of coronary heart disease: an economic evaluation using data from the CE-MARC study
    Walker, Simon
    Girardin, Francois
    McKenna, Claire
    Ball, Stephen G.
    Nixon, Jane
    Plein, Sven
    Greenwood, John P.
    Sculpher, Mark
    HEART, 2013, 99 (12) : 873 - 881
  • [46] Legacy of Lipid Lowering in Preventing Fatal and Non Fatal Cardiovascular Events in Individuals Without Cardiovascular Disease During 3 Years of Post Trial Observation in the HOPE 3 (Heart Outcomes Prevention Evaluation) Study
    Bosch, Jackie
    Lonn, Eva M.
    Jung, Hyejung
    Yusuf, Salim
    CIRCULATION RESEARCH, 2019, 125 (12) : E108 - E108
  • [47] Evaluation of 9 biomarkers for predicting 10-year cardiovascular risk in patients undergoing coronary angiography: Findings from the LUdwigshafen RIsk and Cardiovascular Health (LURIC) study
    Hartaigh, Briain O.
    Thomas, G. Neil
    Bosch, Jos A.
    Hemming, Karla
    Pilz, Stefan
    Loerbroks, Adrian
    Kleber, Marcus E.
    Grammer, Tanja B.
    Fischer, Joachim E.
    Silbernagel, Guenther
    Tomaschitz, Andreas
    Maerz, Winfried
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (03) : 2609 - 2615
  • [48] Legacy of Lipid Lowering in Preventing Fatal and Non Fatal Cardiovascular Events in Individuals Without Cardiovascular Disease During 3 Years of Post -Trial Observation in the Hope 3 (Heart Outcomes Prevention Evaluation 3) Study
    Bosch, Jackie J.
    Lonn, Eva M.
    Jung, Hyejung
    Yusuf, Salim
    CIRCULATION, 2019, 140
  • [49] Economic evaluation of a polypill for the treatment of patients with established or at high risk of cardiovascular disease (CVD): a UK-National Health Service study
    Crossan, Catriona
    Dehbi, Hakim-Moulay
    Williams, Hilarie
    Poulter, Neil
    Thom, Simon
    Lord, Joanne
    JOURNAL OF HUMAN HYPERTENSION, 2017, 31 (10) : 664 - 664
  • [50] Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target? An Antagonist View From the HOPE-3 Trial (Heart Outcomes Evaluation-3)
    Lonn, Eva M.
    Yusuf, Salim
    CIRCULATION, 2016, 134 (18) : 1311 - 1313
12345